Must we Treat Uremic Dyslipidemia?

Grutzmacher P. , Marz W. , Peschke B. . Lipoproteins and apolipoproteins during the progression of chronic renal disease. Nephron 1988; 50: 103–11.

Attman P. , Alaupovic P. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia. Relation to renal function and dialysis. Nephron 1991; 57: 401–10.

Kasiske B.L. , Keane W.F. Causes, consequenes, and treatment of hyperlipidemia in patients with renal disease. In: Andreucci V.E. , Fine , eds. International yearbook of nephrology. Dordrecht: Kluwer Academic Publishers, 1991: 179–96.

Golper T.A. Therapy for uremic hyperlipidemia. Nephron 1984; 38: 217–25.

Wheeler D.C. , Sweny P. , Varghese Z. , Moorhead J.F. Hyperlipidemia and atherosclerosis in chronic dialysis patients. In: Maher J.F. , ed. Replacement of renal function by dialysis. Dordrecht: Kluwer Academic Publishers, 1989; 798–807.

Mujais S.K. , Sabatini S. , Kurtzman N.A. Pathophysiology of the uremic syndrome. In: Brenner B.M. , Rector F.C. , eds. The kidney. Philadelphia: WB Saunders, 1986; 1593–4.

Roh Dave . Is atherogenesis accelerated in hemodialysis patients? Int J Artif Organs 1992; 15: 323–6.

Holme I. An analysis of randomized trials evaluating the effects of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation 1990; 82: 1916–24.

Muldoon M.F. , Manuck S.B. , Matthews K.A. Lowering cholesterol concentration and mortality: a quantitative review of primary prevention trials. Br Med J 1990; 301: 309–14.

Oliver M.F. Might treatment of hypercholesterolaemia increase noncardiac mortality? Lancet 1991; 337: 1529–31.

Standberg T.E. , Salomaa V.V. , Nalkkatinen V.A. , Vanhanen H.T. , Sarna S.J. , Miettinen T.A. Long-term mortality after 5-years multifactorial primary prevention of cardiovascular diseases in middle-aged men. JAMA 1991; 266: 1225–9.

Smith G.D. , Pekkanen J. Should there be a moratorium on the use of cholesterol-lowering drugs? Br Med J 1992; 304: 431–4.

Oliver M.F. Doubts about preventing coronary heart disease. Br Med J 1992; 304: 393–4.

Yusuf S. , Furberg C.D. Single factor trials: control through life-style changes. In: Olsson A.G. , ed. Atherosclerosis. Biology and clinical science. Edinburgh: Churcill Livingstone, 1987; 389–91.

Canner P.L. , Berge G.K. , Wenger N.K. , Stamler J. , Friedman L. , Prineas R.J. . Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 18: 1245–55.

Carlson L.A. , Rosenhamer G. Reduction of mortality in the Stockolm Ischaemic Heart Disease Secondary Prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1989; 223: 405–18.

Buchwald H. , Varco R.L. , Matts J.P. , Long J.M. , Fitch L.L. , Campbell G.S. . Effect of partial ileal bypass on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia (POSCH). N Engl J Med 1990; 323: 946–55.

Ulbricht T.I.V. , Southgate D.A.T. Coronary heart disease: seven dietary factors. Lancet 1991; 338: 985–92.

Ramsay L.E. , Yeo W.W. , Jackson P.R. Dietary reduction of serum cholesterol concentration: time to think again. Br Med J 1991; 303: 953–7.

Avins A.L. , Haber R.J. , Hulley S.B. The status of hypertriglyceridemia as a risk factor for coronary heart disease. Clin Lab Med 1989; 9: 153–68.

Austin M.A. , Goto Y. , Lenfant C. , Tyloler H.A. The hypertriglyceridemias: risk and management. Epidemiology. Am J Cardiol 1991; 68: 22–5A.

International Committee for the evaluation of hypertriglyceridemias as a vascular risk factor. The hypertri-glyceridemias: risk and management. Am J Cardiol 1991; 68: 1–42A.

Assmann G. , Gotto A.J. , Paoletti R. The hypertriglyceridemias: risk and management. Introduction. Am J Cardiol 1991; 68: 1–4A.

Grundy S.M. Management of hyperlipidemia of kidney disease. Kidney Int 1990; 37: 847–53.

Riesen W.F. , Mordasini R. Hyperlipidemia in renal failure: phenotypes and pathogenic mechanism. Contrib Nephrol 1984; 41: 312–20.

Ibles L.S. , Simons L.A. , King J.O. , Williams P.F. , Neale F.C. , Stewart J.H. Studies on the nature and causes of hyperlipidemia in uremia, maintenance dialysis and renal transplantation. Q J Med 1975; 44: 601–14.

Hahn R. , Oette K. , Mondorf H. , Finke K. , Seiberth H.G. Analysis of cardiovascular risk factors in chronic hemodialysis patients with special attention to the hyperlipoproteinemias. Atherosclerosis 1983; 48: 279–88.

Papadopoulus N.M. , Bordr W.Z. , Elin R.J. , Diamond L.H. An abnormal lipoprotein in the serum of uremic patients maintained on chronic hemodialysis. Ann Intern Med 1980; 92: 634–5.

Ponticelli C. , Barbi G. , Cantaluppi A. , Donati C. , Annoni G. , Brancaccio D. Lipid abnormalities in maintenance dialysis and renal transplant recipients. Kidney Int 1978; 13: S72–8 (suppl 8).

Avram M.M. , Fein P.A. , Anignani A. . Cholesterol and lipid disturbances in renal disease: the natural history of uremic dyslipidemia and the impact of hemodialysis and CAPD. Am J Med 1989; 87: (5N) 55–61N.

Guarnieri G.F. , Moracciello M. , Campanacci L. . Lecithin-cholesterol acyl-transferare (LCAT) activity in chronic uremia. Kidney Int 1978; 8: 526–30.

Nestel P.J. , Fidge N.H. , Tan M.H. Increased lipoprotein-remnant formation in chronic renal failure. N Engl J Med 1982; 307: 329–33.

Ron D. , Oren D. , Aviram M. , Better O.S. , Brook J.G. Accumulation of lipoprotein remnants in patients with chronic renal failure. Atherosclerosis 1983; 46: 67–75.

Senti M. , Romero R. , Pedro-Botet J. , Pelegri A. , Noguès X. , Rubiès-Prat J. Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int 1992; 41: 1394–9.

Cutler R.E. Lipid disorders in renal disease: prevalence, pathogenesis and diagnosis. Dial Transplant 1988; 17: 533–6.

Vosnides G. , Cameron J.S. Hyperlipidemia in renal disease. Med J Aust 1974; 2: 1985.

Parra F.U. , Mezdour H. , Cachera C. . Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis. Clin Chem 1987; 33: 721.

Parsy D. , Dracon M. , Cachera C. . Lipoprotein abnormalities in chronic hemodialysis patients. Neprol Dial Transplant 1988; 3: 51–6.

Murase T. , Cattran D.C. , Rubenstein B. , Steiner G. Inhibition of lipoprotein lipase by uremic plasma, a possible cause of hypertriglyceridemia. Metabolism 1975; 24: 1279–86.

Crawford G.A. , Mahony J.F. , Stewart J.H. Impaired lipoprotein lipase activation by uremic and post-transplant sera. Clin Sci 1981; 60: 73–80.

Akmal M. , Kasim S.E. , Soliman A.R. , Massry S.G. Excess parathyroid hormone adversely affects lipid metabolism in chroic renal failure. Kidney Int 1990; 37: 854–8.

Ramos J.M. , Heaton A. , Mc Gurk J.G. , Ward M.K. , Kerr D.N.S. Sequential changes in serum lipids and their subfractions in patients receiving continuous ambulatory peritoneal dialysis. Nephron 1983; 35: 20–3.

Lindholm B. , Norbeck H.E. Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis. Acta Med Scand 1986; 220: 143–51.

Saku K. , Sasaki J. , Naito S. , Avakawa K. Lipoprotein and apolipoprotein losses during continuous ambulatory peritoneal dialysis. Nephron 1989; 51: 220–4.

Breckinridge W.C. , Roncari D.A.K. , Khanna R. , Oreopoulos D.G. The influence of continuous ambulatory peritoneal dialysis on plasma lipoproteins. Atherosclerosis 1982; 45: 249–58.

Gurland H.J. , Brunner F.P. , Dehn H.V. . Combined report on regular dialysis and transplantation in Europe. Proc EDTA 1973; 10: 17–59.

Burton B.T. , Krueger K.K. , Bryan F.A. Jr. , National Registry of long-term dialysis patients. JAMA 1971; 218: 718–22.

Degoulet P. , Legrain M. , Reach I. . Mortality risk factors in patients treated by chronic hemodialysis. Nephron 1982; 31: 103–10.

Disney APS. Dialysis treatment in Australia, 1982 to 1988. Am J Kidney Dis 1990; 15: 402–9.

Kjellstrand C.M. , Hylander B. , Collins A.C. Mortality on dialysis - On the influence of early start, patientchar-acteristics, and transplantation and acceptance rates. Am J Kidney Dis 1990; 15: 483–90.

Ritz E. , Augustin J. , Bommer J. , Grasso A. , Haberbosch W. Should hyperlipidemia of renal failure be treated. Kidney Int 1985; 28(S17): 584–7.

Lindner A.L. , Charra B. , Sherrand D.J. , Schribner B.H. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697–701.

Broyer M. , Brunner F.P. , Brynger H. . Combined report on regular dialysis and transplantation in Europe. Proc EDTA 1982; 19: 260.

Brunner F.P. , Brynger H. , Chantler C. . Combined report on regular dialysis and transplantation in Europe Proc EDTA 1979; 16: 4–68.

Burke J.F. , Francos G.C. , Moore L.L. Accelerated atherosclerosis in chronic dialysis patients. Another look. Nephron 1978; 21: 181–8.

Vincenti F. , Amend W. , Abele J. , Fedusca N.J. , Salvatierra O. The role of hypertension in hemodialysis-associated atherosclerosis. Am J Med 1980; 68: 363–9.

Nicholls A.J. , Catto G.R. , Edward N. , Engeset J. , Mc Leod M. Accelerated atherosclerosis in long-term dialysis and renal transplant patients: fact or finction? Lancet 1980; i; 276–8.

Bergesio F. , Ciuti R. , Salvadori M. . Are lipid abnormalities reliable cardiovascular risk factors in dialysis patients? Int J Artif Organs 1989; 12: 677–82.

Rostand S.G. , Gretes J.G. , Katharine A.K. , Edwin A.R. , Andreoli T.E. Ischemic heart disease in patients with uremia undergoing maintenance hemodialysis. Kidney Int 1979; 16: 600–11.

Kindler J. , Sieberth H.G. , Glockner W.M. , Vlaho M. , Pelzer R. Does atherosclerosis caused by dialysis limit this treatment? Proc EDTA 1982; 19: 168–72.

Ludin A.P. , Friedman E.A. Is progressive atherosclerosis and cardiovascular death an inevitable sequence in patients on maintenance hemodialysis? Proceedings Third Uremia conference. Milan: Wichtig, 1981; 246–50.

Ritz E. , Horsch A. , Heuck C.C. What is the evidence for accelerated atherogenesis in uremia? Proceedings of the 3rd Capri Uremia Conference. Milan: Wichtig, 1981; 241–5.

Avram M.M. , Burrell D. , Slater P.A. . The role of cholesterol and lipids in the atherogenicity of continuous ambulatory peritoneal dialysis patients: Update 1990. In: Avram M.M. , Giordano C. , eds. Ambulatory peritoneal dialysis. New York, NY: Plenum Medical, 1990; 3–10.

Frank W.M. , Rao T.K.S. , Manis T. . Relationship of plasma lipids to renal function and length of time on maintenance hemodialysis. Am J Clin Nutr 1978; 31: 1886–92.

Rostand S.G. , Katharine A.K. , Edwin A.R. Relationship of coronary risk factors to hemodialysis-associated ischemic heart disease. Kidney Int 1982; 22: 304–8.

Levine J. , Falk B. , Henriquez M. High density lipoproteins. Correlation with cardiovascular disease in hemodialysis patients. Trans ASAIO 1978; 14: 43–9.

Rostand S.G. , Katharine A.K. , Edwin A.R. Dialysis-associated ischemic heart disease: insight from coronary angiography. Kidney Int 1984; 25: 653–9.

Somer J.B. , Aijken J.M. , Abbot L.K. , Charlesworth J.A. , Mac Donald G. , Blacket R.B. Lipoprotein lipids in chronic renal failure and hemodialysis: the influence of etiology and implication for atherogenesis. Atherosclerosis 1979; 34: 353–64.

Goldberg A.P. , Applebaum-Bowden D.M. , Prat V. . Increase in lipoprotein-lipase during clofibrate treatment of hypertriglyceridemia in patients on hemodialysis. N Engl J Med 1979; 301: 1073–6.

Okubo M. , Tsukamoto T. , Yoneda T. . Deranged fat metabolism and the lowering effect of carbohydrate-poor diet on serum triglycerides in patients with chronic renal failure. Nephron 1980; 25: 8–14.

Sanfelippo M.L. , Swanson R.S. , Reaven G.M. Responses of plasma triglycerides to dierary change in patients on hemodialysis. Kidney Int 1978; 14: 180–6.

Chan M.K. , Varghese Z. , Baillod R.A. , Moorhead J.F. Atherosclerosis in dialysis and renal transplant patients. Lancet 1980; i: 591–2.

Attman P.O. , Alaupovic P. , Gustafson A. Serum apolipoprotein profile of patients with chronic renal failure. Kidney Int 1987; 32: 368–75.

Avram M.M. , Goldwasser P. , Burrel D.E. , Antignani A. , Fein P.A. , Mittman N. The uremic dislipidemia: a cross-sectional and longitudinal study. Am J Kidney Dis 1992; 4: 324–35.

Sanfelippo M.L. , Swenson R.S. , Reaven G.M. Reduction of plasma triglycerides by diet in subjects with chronic renal failure. Kidney Int 1977; ii: 54–61.

Tsukamoto Y. , Okubo M. , Yoneda T. . Effects of a polyunsatured fatty acid-rich diet on serum lipids in patients with chronic renal failure. Nephron 1982; 31: 236–41.

Dornan T.L. , Gokal R. , Pearce J.S. , Oliver D.O. , Ledingham J.G.G. , Mann J.I. Long-term dietary treatment of hyperlipidemia in patients treated with chronic hemodialysis. Br Med J 1980; 281: 1044.

Cattram D.C. , Steiner G. , Fenton S.S.A. , Ampil M. Dialysis hyperlipidemia: response to dietary manipulation. Clin Nephrol 1980; 13: 177–82.

Gokal R. , Mann J.I. , Oliver D.O. , Ledingham J.G.G. Dietary treatment of hyperlipidemia in chronic hemodialysis patients. Am J Clin Nutr 1978; 31: 1915–8.

Di Giulio S. , Boulu R. , Drueke T. . Clofibrate treatment of hyperlipidemia in chronic renal failure. Clin Nephrol 1977; 8: 504–9.

Pasternack , Vanttinen T. , Solakivi T. , Kuusi T. , Korte T. Normalization of lipoprotein lipase and hepatic lipase by gemfibrozil results in correction of lipoprotein abnormalities in chronic renal failure. Clin Nephrol 1987; 27: 163–8.

Grutzmacher P. , Scheuermann E.H. , Siede W. . Lipid lowering treatment with bezafibrate in patients on chronic hemodialysis: Pharmakinetics and effects. Klin Wochenschr 1986; 64: 910–6.

Grutzmacher P. , Scheuermann E. , Land D. Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients. Proc EDTA 1981; 18: 169–75.

Norbeck H.E. , Anderson P. Treatment of uremic hypertriglyceridaemia with bezafibrate. Atherosclerosis 1982; 44: 125–36.

Williams A.J. , Baker F. , Walls J. The short-term effect of bezafibrate on the hypertriglyceridaemia of moderate to severe uraemia. Br J Clin Pharmacol 1984; 18: 361–7.

Chan M.K. Sustained-release bezafibrate corrects lipid abnormalities in patients on continuous ambulatory peritoneal dialysis. Nephron 1990; 56: 56–61.

Pelegri A. , Romero R. , Senti M. , Nogues X. , Pedro-Botet J. , Rubies-Prat J. Effect of bezafibrate on lipoprotein(a) and triglyceride-rich liporpoteins, including intermediate-density lipoproteins, in patients with chronic renal failure receiving haemodialysis. Nephrol Dial Trap 1992; 7: 623–6.

Wanner C. , Wieland H. , Nauck M. , Schaeffer G. , Schol-Imeyer P. , Hoerl W.H. Effective hypolipidaemic therapy with beclobrate in haemodialysis patients: interference with L-carnitine. Neprhol Dial Trap 1990; 5: 588–93.

Langer T. , Levy R. Acute muscular syndrome associated with administration of clofibrate. N Engl J Med 1968; 279: 856–8.

Pierides A.M. , Alvarez-Ude F. , Kerr D.N.S. Clofibrate induced muscle damage in patients with chronic renal failure. Lancet 1975; ii: 1279–82.

Kijima Y. , Sasaoka T. , Kanayama M. , Kubota S. Untoward effects of clofibrate in hemodialyzed patients. N Engl J Med 1977; 296: 515.

Magarian G.J. , Lucas L.M. , Colley C. Gemfibrozil-induced myopathy. Arch Intern Med 1991; 151: 1873–4.

Sherrand D.J. , Goldberg A.B. , Hass L.B. , Brunzell J.D. Chronic clofibrate therapy in maintenance hemodialysis patients. Nephron 1980; 25: 219–21.

Abshagen U. , Bablok W. , Koch K. . Disposition pharmacokinetics of bezafibrate in man. Eur J Clin Pharmacol 1979; 16: 31–8.

Anderson P. , Norbeck H.E. Clinical pharmacokinetics of bezafibrate in patients with impaired renal function. Eur J Clin Pharmacol 1981; 2: 209–13.

Hamazaki T. , Nakazawa R. , Tateno S. . Effects of fish oil rich in eicosapentaenoic acid on serum lipid in hyperlipemic patients. Kidney Int 1984; 26: 81–4.

Rylance PB , Gordge M.P. , Saynor R. . Fish oil modifies and reduces platelet aggregability in hemodialysis patients. Nephron 1986; 43: 196–202.

Rolf N. , Tenschert W. , Lison A.E. Results of a long-term administration of omega-3 fatty acids in haemodialysis patients with dyslipoproteinaemia. Nephrol Dial Transplant 1990; 5: 797–801.

Schneider H. , Schmitt Y. Effect of highly unsatured fatty acids on the lipoprotein metabolism of patients receiving chronic haemodialysis (Abstract). Nephrol Dial Transplant 1992; 7: 738–9.

Friedman E.A. , Feinstein E.L. , Beyer M.M. . Charcoal induced lipid reduction in uremia. Kidney Int 1978; 13: S170–6 (suppl 8).

Guarnieri G. , Toigo G. , Crapesi L. . Carnitine metabolism in chronic renal failure. Kidney Int 1987; 32: S116–27 (suppl 22).

Golper T.A. , Wolfson M. , Ahmad S. . Multicenter trial of L-carnitine in maintenance hemodialysis patients. Carnitine concentrations and lipid effects. Kidney Int 1990; 38: 904–11.

Wanner C. , Hoerl W.H. Carnitine abnormalities in patients with renal insufficiency: pathophysiological and therapeutical aspects. Nephron 1988; 50: 89–102.

Boehmer T. , Bergrem H. , Eiklid K. Carnitine deficiency induced during intermittent haemodialysis for renal failure. Lancet 1978; i: 126–8.

Wanner C. , Hoerl W.H. Potential role of carnitine in patients with renal insufficiency. Klin Wochenschr 1986; 64: 579–86.

Wanner C. , Foerstner-Wanner S. , Roessle C. , Fuerst P. , Schollmeyer P. , Hoerl W.H. Carnitine metabolism in patients with chronic renal failure: effects of L-carnitine supplementation. Kidney Int 1987; 32: (Suppl 22): 132–5.

Roessle C. , Kohse K.P. , Kapp W. . Disturbed carnitine metabolism in hemodialysis patients. Clin Nutr 1986; (Suppl 5): 136.

Wanner C. , Foerstner-Wanner S. , Schaeffer G. , Schol-Imeyer P. , Hoerl W.H. Serum-free carnitine, carnitine esters and lipids in patients on peritoneal and hemodialysis. Am J Nephrol 1986; 6: 206–11.

Ahmad S. , Golper T. , Hirschberg R. . Efficacy of L-carnitine in hemodialysis: a multicenter controlled clinical trial (Abstract). Kidney Int 1987; 31: 266.

Pande S.V. , Parvin R. Clofibrate enhancement of mitochondrial carnitine transport system of rat liber and augmentation of liver carnitine and gamma-butyrobe-taine hydroxylase activity by thyroxine. Biochim Bio-phys Acta 1980; 617: 363–70.

Litin S.C. , Anderson D.F. Nicotinic acid-associated myopathy: a report of three cases. Am J Med 1989; 86: 481–3.

Giorcelli G. , Vacha G. , Icardi G.P. Drug treatment of hypertriglyceridemia in chronic uraemic patients: preliminary report on D, L-carnitine and thiadenol. Proc EDTA 1980; 17: 367.

Kleiner M.J. , Tate S.S. , Sullivan J.F. , Chami J. Vitamin B6 deficiency in maintenance dialysis patients: metabolic effects of repletion. Am J Clin Nutr 1980; 33: 1612.

Schrader J. , Stibbe W. , Armstrog V.W. . Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemodiltration. Kidney Int 1988; 33: 890–6.

Schmitt Y. , Schneider H. The influence of low molecular weight hepatin on the lipoprotein metabolism of chronic hemodialysis patients. Arztl Lab 1990; 36/8.

Harter H.R. , Goldberg A.P. Endurance exercise training, an effective therapeutic modality for hemodialysis patients. Med Clin North Am 1985; 69: 1259–75.

Goldberg A.P. , Hagberg J.M. , Delmez J.A. , Haynes M.E. , Harter H.R. Metabolic effects of exercise training in hemodialysis patients. Kidney Int 1980; 18: 754.

Gyntelberg F. , Brennan R. , Holloszy J.O. , Schonfeld G. , Rennie M.J. , Weidman S.W. Plasma triglyceride lowering by exercise despite increased food intake in patients with type IV hyperlipoproteinemia. Am J Clin Nutr 1977; 30: 716.

O'Connor P. , Feely J. , Sheperd J. Lipid lowering drugs. Br Med J 1990; 300: 667–72.

Rubenfire M. , Maciejko J.J. , Blevins R.D. . The effect of pravastatin on plasma lipoprotein and apolipoprotein levels in primary hypercholesterolemia. Arch Intern Med 1991; 151: 2234–40.

Grundy S.M. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988; 319: 24–33.

Pierce L.R. , Wysowski D.K. , Gross T.P. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264: 71–5.

Bridgman J.F. , Rosen S.M. , Thorp J.M. Complications during clofibrate treatment of nephrotic-syndrome hy-perlipoproteinaemia. Lancet 1972; 2: 506–9.

Wanner C. , Wieland M. , Schollmeyer P. , Morl W.M. Effect of lovastatin on the lipoprotein system of hyperlipidemic hemodialysis patients. Kidney Int 1990; 37: 323 (A).

Innocenti M. , Mazzoni A. , Bianchi S. Iperlipidemia nel paziente in emodialisi: risultati dopo un anno di terapia con simvastatina (Abstract). Giorn It Nefrol 1991; 8S-1: 422.

Patrone E. , Fiorini F. , Ardu F. , Castelluccio A. La simvastatina (SV) nella terapia dell'iperlipemia (I) nei pazienti uremici in trattamento emodialitico (HD) (Abstract). Giorn It Nefrol 1991; 8S-1: 330.

d'Aloya G. , Beccari M. , Cavaliere G. . La pravastati-na è efficace e sicura nella correzione della dislipidemia dei dializzati (Abstract). Giorn It Nefrol 1992; 9 S-2: 109.

Wanner C. , Hoerl W.H. , Luley C.H. , Wieland H. Effects of HMG-CoA reductase inhibitors in hypercholestero-lemic patients on hemodialysis. Kidney Int 1991; 39: 754–60.

Sperber A.D. , Zuili I. , Bearman J.E. , Shany S. The effect of an antacid containing aluminum hydroxide on plasma cholesterol and lipoproteins. Curr Ther Res 1988; 44: 426–33.

Sperber A.D. , Henkin Y. , Zuili I. , Bearman J.E. , Shany S. The hypocholesterolemic effect of an antacid containing aluminum hydroxide. Am J Med 1991; 91: 597–604.

Bell L. , Hastelson C.E. , Hastelson C.J. , Macres M. , Keane W.F. Cholesterol-lowering effects of calcium carbonate in patients with mild to moderate hypercholesterolemia. Arch Intern Med 1992; 152: 2441–4.

Josephson M.A. , Fellner S.K. , Dasgupta A. Improved lipid profiles in patients undergoing high-flux hemodialysis. Am J Kidney Dis 1992; 4: 361–6.